TY - JOUR
T1 - Quantitative analysis of cytomegalovirus viremia in lung transplant recipients
AU - Bailey, Thomas C.
AU - Buller, Richard S.
AU - Ettinger, Neil A.
AU - Trulock, Elbert P.
AU - Gaudreault-Keener, Monique
AU - Langlois, Teri M.
AU - Rossiter Fornoff, Jane E.
AU - Cooper, Joel D.
AU - Storch, Gregory A.
PY - 1995/4
Y1 - 1995/4
N2 - A quantitative culture method was used to test serial blood specimens from 28 lung transplant recipients at risk of cytomegalovirus (CMV) infection (donor [D] or recipient [R] seropositive for CMV). Viremia occurred in 26 (93%) of 28 patients. Highest levels were seen when the donor was seropositive. The median of individual maximum levels was 2.13 infectious centers (ICs)/10s leukocytes for D+/R· patients (interquartile range [iqr], 0.12-21.77), 1.01 for D+/R+ (iqr, 0.32.32), and 0.10 for D·/R+ [iqr, 0.07-0.36; P =.030, Kruskal-Wallis test). Higher levels were seen in patients with biopsy-proven CMV pneumonitis compared with those with negative biopsies (mean, 0.24 [SD 0.51] ICs/105 leukocytes vs. 0.01 [SD 0.03]; P =.039, Wilcoxon test) and with symptomatic CMV episodes compared with asymptomatic episodes (median, 0.34 ICs/I0s [iqr, 0.11-0.61] vs. 0.08 ICs/105 [iqr, 0.03-0.13]; P =.045, Wilcoxon test). Further studies are required to determine whether quantification of CMV viremia by this method will be of practical value in the recognition of significant CMV infection in lung transplant recipients.
AB - A quantitative culture method was used to test serial blood specimens from 28 lung transplant recipients at risk of cytomegalovirus (CMV) infection (donor [D] or recipient [R] seropositive for CMV). Viremia occurred in 26 (93%) of 28 patients. Highest levels were seen when the donor was seropositive. The median of individual maximum levels was 2.13 infectious centers (ICs)/10s leukocytes for D+/R· patients (interquartile range [iqr], 0.12-21.77), 1.01 for D+/R+ (iqr, 0.32.32), and 0.10 for D·/R+ [iqr, 0.07-0.36; P =.030, Kruskal-Wallis test). Higher levels were seen in patients with biopsy-proven CMV pneumonitis compared with those with negative biopsies (mean, 0.24 [SD 0.51] ICs/105 leukocytes vs. 0.01 [SD 0.03]; P =.039, Wilcoxon test) and with symptomatic CMV episodes compared with asymptomatic episodes (median, 0.34 ICs/I0s [iqr, 0.11-0.61] vs. 0.08 ICs/105 [iqr, 0.03-0.13]; P =.045, Wilcoxon test). Further studies are required to determine whether quantification of CMV viremia by this method will be of practical value in the recognition of significant CMV infection in lung transplant recipients.
UR - http://www.scopus.com/inward/record.url?scp=0028905155&partnerID=8YFLogxK
U2 - 10.1093/infdis/171.4.1006
DO - 10.1093/infdis/171.4.1006
M3 - Article
C2 - 7706777
AN - SCOPUS:0028905155
SN - 0022-1899
VL - 171
SP - 1006
EP - 1010
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -